ALLR
Allarity Therapeutics, Inc.
Price Chart
Latest Quote
$0.96
Current Price| Previous Close | $1.00 |
| Open | $1.00 |
| Day High | $1.02 |
| Day Low | $0.94 |
| Volume | 297,233 |
Stock Information
| Shares Outstanding | 16.08M |
| Total Debt | $1.39M |
| Cash Equivalents | $16.89M |
| Net Income | $-15.31M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $15.50M |
| P/E Ratio | 0.11 |
| EPS (TTM) | $9.11 |
| Exchange | NCM |
📊 Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.11 |
| Debt to Earnings | -0.05 |
| Current Ratio | 2.06 |
| Quick Ratio | 2.01 |
| Return on Equity | -207.56% |
| Avg FCF Growth | 4.64% |
| FCF Yield | -113.84% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $0.96 | 309,500 |
| 2026-01-30 | $1.00 | 235,600 |
| 2026-01-29 | $1.04 | 244,300 |
| 2026-01-28 | $1.09 | 251,100 |
| 2026-01-27 | $1.20 | 52,000 |
| 2026-01-26 | $1.19 | 95,100 |
| 2026-01-23 | $1.20 | 100,900 |
| 2026-01-22 | $1.24 | 87,600 |
| 2026-01-21 | $1.18 | 76,900 |
| 2026-01-20 | $1.16 | 107,000 |
| 2026-01-16 | $1.18 | 51,000 |
| 2026-01-15 | $1.18 | 59,200 |
| 2026-01-14 | $1.21 | 91,000 |
| 2026-01-13 | $1.21 | 171,100 |
| 2026-01-12 | $1.14 | 134,300 |
| 2026-01-09 | $1.17 | 73,800 |
| 2026-01-08 | $1.19 | 131,100 |
| 2026-01-07 | $1.16 | 154,100 |
| 2026-01-06 | $1.11 | 72,000 |
| 2026-01-05 | $1.12 | 134,100 |
About Allarity Therapeutics, Inc.
Allarity Therapeutics, Inc., a clinical-stage precision medicine pharmaceutical company, focuses on developing novel anti-cancer therapeutics for patients with unmet medical needs. The company develops drugs for the personalized treatment of cancer using drug specific companion diagnostics generated by its proprietary drug response predictor technology. Its lead drug candidate includes Stenoparib, a novel dual inhibitor of poly-ADP-ribose polymerase (PARP1/2) that is being evaluated in a phase 2 clinical trial in patients with advanced and recurrent ovarian cancer. The company also develops stenoparib- DRP, a companion diagnostic product used in select patients for stenoparib treatment. Allarity Therapeutics, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.
Income Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 |
| Operating Revenue | $0 | $0 | $0 | $0 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $653,000 | $498,000 | $223,000 | $640,000 |
| Total Expenses | $17,538,000 | $17,129,000 | $16,892,000 | $26,556,000 |
| Other Income Expense | $-7,238,000 | $5,787,000 | $-494,000 | $2,028,000 |
| Net Non Operating Interest Income Expense | $-120,000 | $-476,000 | $-193,000 | $-1,987,000 |
| Interest Expense Non Operating | $653,000 | $498,000 | $223,000 | $640,000 |
| Operating Expense | $17,538,000 | $17,129,000 | $16,892,000 | $26,556,000 |
| General And Administrative Expense | $11,442,000 | $10,026,000 | $9,962,000 | $12,360,000 |
| Other Non Operating Income Expenses | - | $-591,000 | - | $-474,000 |
| Total Other Finance Cost | - | - | - | $1,347,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-24,515,000 | $-11,901,000 | $-16,058,000 | $-26,648,000 |
| Net Interest Income | $-120,000 | $-476,000 | $-193,000 | $-1,987,000 |
| Interest Income | $533,000 | $22,000 | $30,000 | $0 |
| Normalized Income | $-17,387,768 | $-16,939,620 | $-15,606,743 | $-28,474,460 |
| Net Income From Continuing And Discontinued Operation | $-24,515,000 | $-11,901,000 | $-16,058,000 | $-26,648,000 |
| Total Operating Income As Reported | $-27,241,000 | $-17,129,000 | $-34,463,000 | $-26,556,000 |
| Net Income Common Stockholders | $-25,154,000 | $-20,416,000 | $-21,051,000 | $-26,648,000 |
| Net Income | $-24,515,000 | $-11,901,000 | $-16,058,000 | $-26,648,000 |
| Net Income Including Noncontrolling Interests | $-24,515,000 | $-11,901,000 | $-16,058,000 | $-26,648,000 |
| Net Income Continuous Operations | $-24,515,000 | $-11,901,000 | $-16,058,000 | $-26,648,000 |
| Pretax Income | $-24,896,000 | $-11,818,000 | $-17,579,000 | $-26,515,000 |
| Special Income Charges | $-9,703,000 | $0 | $-16,591,000 | $1,005,000 |
| Interest Income Non Operating | $533,000 | $22,000 | $30,000 | $0 |
| Operating Income | $-17,538,000 | $-17,129,000 | $-16,892,000 | $-26,556,000 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-15.65 | $-6031.31 | $-31799.09 | $-79074.18 |
| Basic EPS | $-15.65 | $-6031.31 | $-31799.09 | $-79074.18 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $-110,768 | $1,339,380 | $-42,743 | $675,540 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-16,996,000 | $-17,661,000 | $-16,802,000 | $-28,271,000 |
| Total Unusual Items | $-7,238,000 | $6,378,000 | $-494,000 | $2,502,000 |
| Total Unusual Items Excluding Goodwill | $-7,238,000 | $6,378,000 | $-494,000 | $2,502,000 |
| Reconciled Depreciation | $9,000 | $37,000 | $60,000 | $106,000 |
| EBITDA (Bullshit earnings) | $-24,234,000 | $-11,283,000 | $-17,296,000 | $-25,769,000 |
| EBIT | $-24,243,000 | $-11,320,000 | $-17,356,000 | $-25,875,000 |
| Diluted Average Shares | $1,606,989 | $3,385 | $662 | $337 |
| Basic Average Shares | $1,606,989 | $3,385 | $662 | $337 |
| Diluted NI Availto Com Stockholders | $-25,154,000 | $-20,416,000 | $-21,051,000 | $-26,648,000 |
| Preferred Stock Dividends | $639,000 | $8,515,000 | $4,993,000 | - |
| Tax Provision | $-381,000 | $83,000 | $-1,521,000 | $133,000 |
| Impairment Of Capital Assets | $9,703,000 | $0 | $17,571,000 | $0 |
| Gain On Sale Of Security | $2,465,000 | $6,378,000 | $16,097,000 | $1,497,000 |
| Research And Development | $6,096,000 | $7,103,000 | $6,930,000 | $14,196,000 |
| Selling General And Administration | $11,442,000 | $10,026,000 | $9,962,000 | $12,360,000 |
| Other Gand A | $11,442,000 | $10,026,000 | $9,962,000 | $12,360,000 |
| Gain On Sale Of Ppe | - | $0 | $1,780,000 | $1,005,000 |
| Other Special Charges | - | - | $800,000 | $141,000 |
| Minority Interests | - | - | - | $0 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $11,811,000 | $-12,622,000 | $-7,659,000 | $-9,351,000 |
| Total Assets | $22,650,000 | $11,862,000 | $14,544,000 | $49,633,000 |
| Total Non Current Assets | $309,000 | $9,891,000 | $9,576,000 | $28,229,000 |
| Goodwill And Other Intangible Assets | $0 | $9,871,000 | $9,549,000 | $28,135,000 |
| Current Assets | $22,341,000 | $1,971,000 | $4,968,000 | $21,404,000 |
| Prepaid Assets | $579,000 | $859,000 | $727,000 | $154,000 |
| Receivables | $2,229,000 | $946,000 | $871,000 | $1,345,000 |
| Taxes Receivable | $813,000 | $946,000 | $871,000 | $1,345,000 |
| Accounts Receivable | $1,416,000 | $0 | - | - |
| Cash Cash Equivalents And Short Term Investments | $19,533,000 | $166,000 | $2,029,000 | $19,905,000 |
| Cash And Cash Equivalents | $19,533,000 | $166,000 | $2,029,000 | $19,555,000 |
| Cash Financial | $19,533,000 | $166,000 | $2,029,000 | $19,555,000 |
| Other Intangible Assets | - | $9,871,000 | $9,549,000 | $28,135,000 |
| Current Deferred Assets | - | $0 | $1,341,000 | $0 |
| Investmentin Financial Assets | - | - | - | $350,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $1,350,000 | $1,300,000 | $3,735,000 | $1,086,000 |
| Current Debt And Capital Lease Obligation | $1,350,000 | $1,300,000 | $2,652,000 | $98,000 |
| Current Debt | $1,350,000 | $1,300,000 | $2,644,000 | - |
| Other Current Borrowings | $1,350,000 | $1,300,000 | $2,644,000 | - |
| Net Debt | - | $1,134,000 | $1,698,000 | - |
| Long Term Debt And Capital Lease Obligation | - | - | $1,083,000 | $988,000 |
| Long Term Debt | - | - | $1,083,000 | $979,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $10,839,000 | $14,613,000 | $12,654,000 | $30,849,000 |
| Total Non Current Liabilities Net Minority Interest | $0 | $446,000 | $1,432,000 | $10,130,000 |
| Non Current Deferred Liabilities | $0 | $446,000 | $349,000 | $1,961,000 |
| Non Current Deferred Taxes Liabilities | $0 | $446,000 | $349,000 | $1,961,000 |
| Current Liabilities | $10,839,000 | $14,167,000 | $11,222,000 | $20,719,000 |
| Other Current Liabilities | $1,000 | $3,083,000 | $374,000 | $11,273,000 |
| Payables And Accrued Expenses | $9,488,000 | $9,784,000 | $8,196,000 | $9,348,000 |
| Interest Payable | $281,000 | $101,000 | $0 | - |
| Payables | $4,256,000 | $8,475,000 | $6,292,000 | $758,000 |
| Total Tax Payable | $74,000 | $59,000 | $41,000 | $60,000 |
| Income Tax Payable | $74,000 | $59,000 | $41,000 | $60,000 |
| Accounts Payable | $4,182,000 | $8,416,000 | $6,251,000 | $698,000 |
| Current Notes Payable | - | $0 | $2,644,000 | - |
| Derivative Product Liabilities | - | - | - | $7,181,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $11,811,000 | $-4,493,000 | $-113,000 | $18,152,000 |
| Total Equity Gross Minority Interest | $11,811,000 | $-2,751,000 | $1,890,000 | $18,784,000 |
| Stockholders Equity | $11,811,000 | $-2,751,000 | $1,890,000 | $18,784,000 |
| Gains Losses Not Affecting Retained Earnings | $-354,000 | $-411,000 | $-721,000 | $-600,000 |
| Other Equity Adjustments | $-354,000 | $-411,000 | $-721,000 | $-600,000 |
| Retained Earnings | $-118,966,000 | $-94,451,000 | $-82,550,000 | $-66,492,000 |
| Preferred Stock Equity | - | $1,742,000 | $2,003,000 | $632,000 |
| Preferred Securities Outside Stock Equity | - | $0 | $0 | $632,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $7,302,797 | $9,811 | $662 | $337 |
| Share Issued | $7,302,797 | $9,811 | $662 | $337 |
| Tangible Book Value | $11,811,000 | $-14,364,000 | $-9,662,000 | $-9,983,000 |
| Invested Capital | $13,161,000 | $-3,193,000 | $3,614,000 | $19,131,000 |
| Working Capital | $11,502,000 | $-12,196,000 | $-6,254,000 | $685,000 |
| Total Capitalization | $11,811,000 | $-2,751,000 | $2,973,000 | $19,763,000 |
| Additional Paid In Capital | $131,130,000 | $90,369,000 | $83,158,000 | $85,243,000 |
| Capital Stock | $1,000 | $1,742,000 | $2,003,000 | $633,000 |
| Common Stock | $1,000 | $0 | $0 | $1,000 |
| Preferred Stock | $0 | $1,742,000 | $2,003,000 | $632,000 |
| Current Accrued Expenses | $5,232,000 | $1,309,000 | $1,904,000 | $8,590,000 |
| Net PPE | $309,000 | $20,000 | $27,000 | $94,000 |
| Gross PPE | $309,000 | $20,000 | $27,000 | $94,000 |
| Other Properties | $309,000 | $20,000 | $27,000 | $94,000 |
| Treasury Shares Number | - | $0 | - | - |
| Capital Lease Obligations | - | $0 | $8,000 | $107,000 |
| Current Capital Lease Obligation | - | $0 | $8,000 | $98,000 |
| Long Term Capital Lease Obligation | - | - | $0 | $9,000 |
| Other Short Term Investments | - | - | $0 | $350,000 |
| Line Of Credit | - | - | - | $0 |
| Investments And Advances | - | - | - | $350,000 |
| Available For Sale Securities | - | - | - | $350,000 |
| Accumulated Depreciation | - | - | - | $-328,000 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-17,650,000 | $-12,745,000 | $-16,835,000 | $-14,886,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-17,352,000 | $-12,745,000 | $-16,817,000 | $-14,886,000 |
| Cash Flow From Continuing Operating Activities | $-17,352,000 | $-12,745,000 | $-16,817,000 | $-14,886,000 |
| Operating Gains Losses | $-2,803,000 | $-5,833,000 | $-18,340,000 | $-2,361,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-298,000 | - | $-18,000 | - |
| Investing Cash Flow | $-298,000 | $0 | $791,000 | $1,005,000 |
| Cash Flow From Continuing Investing Activities | $-298,000 | $0 | $791,000 | $1,005,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repurchase Of Capital Stock | $-3,500,000 | $-6,654,000 | $-1,511,000 | $0 |
| Issuance Of Capital Stock | $40,292,000 | $18,055,000 | $0 | $32,125,000 |
| Financing Cash Flow | $36,792,000 | $10,995,000 | $-1,311,000 | $33,818,000 |
| Cash Flow From Continuing Financing Activities | $36,792,000 | $10,995,000 | $-1,311,000 | $33,818,000 |
| Net Preferred Stock Issuance | $-562,000 | $-5,494,000 | $-1,511,000 | $0 |
| Preferred Stock Issuance | $2,938,000 | $1,160,000 | $0 | - |
| Net Common Stock Issuance | $37,354,000 | $16,895,000 | $0 | $32,125,000 |
| Common Stock Issuance | $37,354,000 | $16,895,000 | $0 | $32,125,000 |
| Net Other Financing Charges | - | - | $-800,000 | $-2,041,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Repayment Of Debt | $-1,340,000 | $-3,699,000 | $0 | $-2,945,000 |
| Issuance Of Debt | $1,340,000 | $1,050,000 | $1,000,000 | $3,998,000 |
| End Cash Position | $19,533,000 | $166,000 | $2,029,000 | $19,555,000 |
| Beginning Cash Position | $166,000 | $2,029,000 | $19,555,000 | $298,000 |
| Effect Of Exchange Rate Changes | $225,000 | $-113,000 | $-189,000 | $-680,000 |
| Changes In Cash | $19,142,000 | $-1,750,000 | $-17,337,000 | $19,937,000 |
| Proceeds From Stock Option Exercised | $0 | $2,243,000 | $0 | $2,765,000 |
| Preferred Stock Payments | $-3,500,000 | $-6,654,000 | $-1,511,000 | $0 |
| Net Issuance Payments Of Debt | $0 | $-2,649,000 | $1,000,000 | $969,000 |
| Net Long Term Debt Issuance | $0 | $-2,649,000 | $1,000,000 | $1,053,000 |
| Long Term Debt Payments | $-1,340,000 | $-3,699,000 | $0 | $-2,945,000 |
| Long Term Debt Issuance | $1,340,000 | $1,050,000 | $1,000,000 | $3,998,000 |
| Net PPE Purchase And Sale | $-298,000 | $0 | $-18,000 | $0 |
| Purchase Of PPE | $-298,000 | $0 | $-18,000 | $0 |
| Change In Working Capital | $63,000 | $3,352,000 | $-328,000 | $5,570,000 |
| Change In Other Working Capital | $207,000 | - | - | - |
| Change In Other Current Liabilities | $0 | $-8,000 | $-99,000 | $-124,000 |
| Change In Other Current Assets | $94,000 | $1,350,000 | $-1,077,000 | $-330,000 |
| Change In Payables And Accrued Expense | $-557,000 | $2,226,000 | $1,466,000 | $5,894,000 |
| Change In Accrued Expense | $3,536,000 | $43,000 | $-4,722,000 | $7,197,000 |
| Change In Payable | $-4,093,000 | $2,183,000 | $6,188,000 | $-1,303,000 |
| Change In Account Payable | $-4,108,000 | $2,165,000 | $6,207,000 | $-1,311,000 |
| Change In Tax Payable | $15,000 | $18,000 | $-19,000 | $8,000 |
| Change In Income Tax Payable | $15,000 | $18,000 | $-19,000 | $8,000 |
| Change In Prepaid Assets | $274,000 | $-190,000 | $-618,000 | $130,000 |
| Change In Receivables | $45,000 | $-26,000 | $0 | $0 |
| Other Non Cash Items | $566,000 | $1,574,000 | $138,000 | $2,059,000 |
| Stock Based Compensation | $71,000 | $-71,000 | $1,752,000 | $6,368,000 |
| Asset Impairment Charge | $9,703,000 | $0 | $17,571,000 | $0 |
| Deferred Tax | $-446,000 | $97,000 | $-1,612,000 | $20,000 |
| Deferred Income Tax | $-446,000 | $97,000 | $-1,612,000 | $20,000 |
| Depreciation Amortization Depletion | $9,000 | $37,000 | $60,000 | $106,000 |
| Depreciation And Amortization | $9,000 | $37,000 | $60,000 | $106,000 |
| Gain Loss On Investment Securities | $-2,677,000 | $-5,654,000 | $-17,010,000 | $-1,592,000 |
| Net Foreign Currency Exchange Gain Loss | $-126,000 | $-179,000 | $450,000 | $95,000 |
| Net Income From Continuing Operations | $-24,515,000 | $-11,901,000 | $-16,058,000 | $-26,648,000 |
| Interest Paid Supplemental Data | - | $34,000 | $85,000 | $262,000 |
| Income Tax Paid Supplemental Data | - | $6,000 | $12,000 | $118,000 |
| Net Intangibles Purchase And Sale | - | $0 | $809,000 | $1,005,000 |
| Sale Of Intangibles | - | $0 | $809,000 | $1,005,000 |
| Gain Loss On Sale Of PPE | - | $0 | $-1,780,000 | $-1,005,000 |
| Net Short Term Debt Issuance | - | - | $0 | $-84,000 |
| Changes In Account Receivables | - | - | - | $0 |